T cell mediated immunotherapy is a promising therapeutic option for multiple myeloma (MM). Gamma-delta T cells (γδ T cells) recognize phosphoantigens and display strong antitumor cytotoxicity. The synthetic agonist Phosphostim (BrHPP) has been shown to selectively activate Vγ9Vδ2 T cells. The aim of this study was to evaluate the expansion capacity and anti-myeloma cell cytotoxicity of circulating γδ T cells from MM patients at different time points throughout the disease, using Phosphostim (BrHPP) and IL-2.
Introduction
Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease with conventional or high dose chemotherapy (HDC). HDC and autologous stem cell transplantation (ASCT) have improved the rate of complete remission, but some multiple myeloma cells (MMC) escape treatment and the majority of MM patients relapse (Attal, et al 1996) . The development of immunotherapy designed to eliminate residual tumor cells may be one hopeful approach to improve MM treatment. One possibility is to trigger anti-MMC specific T cells. In particular, transduction of MMC with CD80 (Tarte, et al 1999) , CD40LG (Cignetti, et al 2005) , or TNFSF9 (also known as 4-1BBL) (Lu, et al 2007) genes makes it possible to obtain anti-MMC αβ T cell lines. MMC express a variety of tumor antigens such as cancer-testis antigens , Pellat-Deceunynck, et al 2000 , van Baren, et al 1999 , or differentiation antigens such as Muc1 (Brossart, et al 2001) or HM-1.24 (Goto, et al 1994 , Hundemer, et al 2006 .
Human T cells bearing the γδ T cell receptor (TCR) may be another source of anti-MMC T cells. They account for 2-5% of peripheral blood lymphocytes and have been shown to exert a major histocompatibility (MHC)-unrestricted natural cytotoxicity against infected and malignant cells (Hayday 2000 , Kunzmann, et al 2000 . Most peripheral γδ T cells display a disulfide-linked Vγ9Vδ2 TCR that recognizes small phosphorylated non-peptide antigens such as mycobacterial antigens (Constant, et al 1994) or isopentenyl-pyrophosphate (IPP), a natural metabolite produced through the mevalonate pathway in eukaryotic cells (Das, et al 2001 . Increased IPP production in tumor cells leads to γδ T cell activation (Gober, et al 2003) . In particular, the Burkitt's lymphoma Daudi cell line is a good activator and target of γδ T cells. Aminobiphosphonates, which are drugs commonly used in MM treatment to prevent osteolytic bone disease, share structural homology with natural γδ T cell ligands and are able to activate γδ T cells in vitro (Kunzmann, et al 2000 , Mariani, et al 2005 . This activation is TCR and monocyte dependent and is mainly induced by targeting intracellular enzymes of the mevalonate pathway (Bukowski, et al 1995 , Mariani, et al 2005 , Miyagawa, et al 2001 . Activated γδ T cells can grow in the presence of IL-2 or IL-15, are potent IFNγ producers (Miyagawa, et al 2001) , and kill tumor cell lines including myeloma cell lines (Kunzmann, et al 2000 , Mariani, et al 2005 , Viey, et al 2005 through mechanisms involving NKG2D and possibly other activating NK receptors binding MICA or MICB expressed by MMC (Girlanda, et al 2005 , Halary, et al 1997 , Rincon-Orozco, et al 2005 . Aminobiphosphonates also stimulate anti-tumor γδ T cells in vivo. A single pamidronate administration followed by low doses of IL-2 in relapsing patients with MM or non-Hodgkin lymphoma triggers the expansion of circulating γδ T cells leading to tumor reduction and to some objective clinical responses (Wilhelm, et al 2003) . However, a successful ex vivo amplification of γδ T cells using pamidronate or zoledronate with IL-2 is reached in only about 50% of patients with MM (Kunzmann, et al 2000 , Mariani, et al 2005 , Wilhelm, et al 2003 . Alternatively, γδ T cells can be directly activated in vitro by pyrophosphomonoesters (Thompson, et al 2006) such as bromohydrin pyrophosphate (BrHPP/Phosphostim). Phosphostim is a synthetic Vγ9Vδ2 TCR agonist that mimics the biological properties of natural phosphoantigens found in hydrosoluble mycobacterial extracts (Espinosa, et al 2001) . Starting from blood samples of patients with renal carcinoma, the use of Phosphostim and IL-2 enabled the selective outgrowth of γδ T cells highly cytotoxic toward autologous primary tumor cells, in 70% of patients (Viey, et al 2005) . In addition, Phosphostim and IL-2 infusions in non-human primates trigger a transient but large expansion of circulating Vγ9Vδ2 T cells, inducing the production of high levels of Th1 cytokines (Sicard, et al 2005) .
The aim of this study was to compare the ability of Phosphostim and zoledronate to expand γδ T cells from normal donors or patients with MM and to evaluate the in vitro anti-MMC cytotoxicity of Phosphostim-expanded γδ T cells from patients with MM.
Materials and Methods

Patients and collection of peripheral blood and bone marrow samples
Buffy coats from 14 age-matched healthy donors (HD) were provided by the French Blood Center (Toulouse, France). Bone marrow and peripheral blood from 18 patients with newlydiagnosed MM (median age 61 years, 10 female patients and 8 male patients) were collected after written informed consent was given. According to Durie-Salmon 
Immunophenotypic analysis
The phenotype of T cells was evaluated with the following monoclonal antibodies (mAbs): phycoerythrin (PE)-conjugated CD3, PE-panγδTCR, PE-CD45RA, PE-CXCR4 (Becton Dickinson San Jose, CA), fluorescein isothiocyanate (FITC) pan-γδTCR, FITC-Vγ2TCR, FITC-Vδ9TCR (Beckman Coulter, Villepinte, France), FITC-CD45RA, FITC-pan CD45, and Cytochrome-conjugated CD27 (Beckman Coulter). Primary MMC were evaluated with the PE-conjugated B-B4 anti-syndecan-1 mAb (Wijdenes, et al 1996) . Anti-CD138 mAb labelled only viable MMC in the bone marrow of patients with MM (Costes, et al 1999 , Jourdan, et al 1998 
Cell lines and primary myeloma cells
XG-1, XG-3, XG-4, XG-5, human myeloma cell lines (HMCLs) were obtained and characterized in our laboratory (Gu, et al 2000 , Rebouissou, et al 1998 , Zhang, et al 1994 . RPMI 8226, RAJI, Daudi, and U266 cell lines were purchased from ATTC (LGC Promochem, Molsheim, France). They were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FCS (Invitrogen), 2 mM L-glutamine, and 2 ng/ml of human recombinant IL-6 (AbCys SA, Paris, France) for the IL-6-dependent HMCLs. Primary myeloma cells were purified from patients' tumor samples as described (Sun, et al 1997) .
Expansion of γδ T cells
PBMCs from healthy donor buffy-coats (n=14) and from patients with MM were seeded at 6 10 /mL in 24-well culture plates at 37°C in 5% CO in RPMI 1640 medium and 10% fetal 
GM-CFU assay
Leucaphaeresis-derived purified CD34 haematopoietic stem cells from 5 patients with MM were assayed for their ability to generate granulocyte and/or macrophage colonies in a semi-solid culture medium with haematopoietic cytokines (GF H4434; StemCell Technologies, Vancouver, BC, Canada). Cells were pre-incubated or not (control) with expanded γδ T cells at 1:30 and 1:5 ratios for 2 hours before semi-solid cultures. The number of granulocyte-macrophage colonies was counted on day 14 of culture.
Statistical analysis
Amplification rates percentages between the different groups were compared with a chisquare test. All the other statistical analyses were done using a Mann-Whitney test. Pvalues <0.05 were considered significant.
Results
γδ T cell and CD3 cell counts in the peripheral blood and bone marrow of patients
γδ T cells were evaluated in the peripheral blood (PB) and in the bone marrow (BM) of 18 patients with newly-diagnosed MM and in PB of 11 age-matched HD. A median γδ T cell percentage of 0.35 % (range 0.04 -2.4 %) was found in PB leucocytes of patients with MM (Table I ). This percentage was not statistically different from that found in 11 healthy donors' PB leucocytes (0.62 %, range 0.4 -1.8%, P = .19, results not shown). A median γδ T cell percentage of 0.38 % (range 0.01 -1.11 %) was found in the bone marrow of these 18 patients. It was not significantly different from that found in the PB of the same patients (P = .27). The median γδ T cell percentages in CD3 cells in PB and BM were 2.1 % and 2.8 %, respectively. Again, these percentages were not statistically different from those found in HD (3.9 %, range 2.4 -11.1 %, P = .28, results not shown). To look for a γδ T cell source for clinical application, γδ T cell counts were evaluated in PB at diagnosis and in the leucaphaeresis products harvested at the time of HSC mobilization with high dose CTX and G-CSF of seven patients with MM ( Table I ). The median γδ T cell percentages in CD3 cells at diagnosis (2.3 %, 0.01 -5.9 %) and at the time of mobilization (1.6 %, 0.02 -6.5 %)
were not statistically different. However, CTX and G-CSF treatment induced a 3-fold depletion in γδ T cell and CD3 cell counts at the time of leucaphaeresis collection (results not shown) in agreement with our previous study . The leucaphaeresis products contained a median number of 68 x 10 6 γδ T cells (range 0.2 -394), i.e., 13-fold less than the median CD34 count.
Expansion of γδ T cells with Phosphostim
Activation of γδ T cells by Phosphostim and IL-2 made it possible to expand γδ T cells from PB at least 100-fold in 14 out of 18 (78%) newly-diagnosed patients. The median expansion was 297-fold, ranging from 10-to 4406-fold ( Table II) . The expanded γδ T cells expressed Vγ9Vδ2 (≥ 80 %, data not shown). Based on our previous experience, we chose this 100-fold amplification cut-off to get enough cells for an adoptive T cell transfer, starting with one leucaphaeresis product, in the prospect for a clinical trial (infusion of at least 3 x 10 9 γδ T cells, Salot et al, submitted). We also assayed γδ T cell amplification using zoledronate and IL-2 for 10 newly-diagnosed patients. The rate of successful amplification (≥ 100 fold) was 70% and was not different from that obtained with Phosphostim and IL-2 (78%, P = .54). In addition, a strong correlation of amplification rates with Phosphostim and zoledronate was found (r = 0.9, P = .001). An efficient amplification of γδ T cells failed in four out of 18 patients (< 100 fold; i.e. 10-, 28-, 39-, and 61-fold). No statistical differences in γδ T cell counts and percentages of γδ T cells in CD3 cells were found in PB cells of patients with a successful or unsuccessful amplification rate. Increasing IL-2 concentrations up to 1000 U/ml instead of 100 U/ml improved the magnitude of amplification without reaching a 100-fold amplification (results not shown).
We then investigated whether γδ T cell expansion could vary throughout disease. We considered 3 groups of MM patients -patients with newly-diagnosed MM (n=18), patients at the time of HSC mobilization with CTX and G-CSF (n=18), and relapsing patients (n=13).
The successful γδ T cell expansion rate (≥ 100 fold) in newly-diagnosed patients (78%) was not significantly different from that obtained in HD (70%, P = .98) and from that obtained in relapsing patients (69%, P = .86). However, the median purity of γδ T cells in the relapsing patient group (21%) was lower than that obtained in the newly-diagnosed patient group (80%) ( Table II , P = .008). The percentage of patients with a successful γδ T cell amplification rate (≥ 100 fold) at the time of HSC mobilization was 50%. It was not statistically lower that those obtained in newly-diagnosed or relapsing patients (P = .17 and P = .28, respectively). Again, the median purity of γδ T cells in this group (11%) was lower than that of the newly-diagnosed patient group (Table II, P <.001).
It was reported that the ability of γδ T cells to be expanded by aminobisphophonates depends on their na ïve/memory phenotype (Mariani, et al 2005) . In this study, the memory phenotype was predominant in γδ T cells of HD that could be expanded with zoledronate and IL-2, whereas the effector phenotype was predominant in cases of poorly expanding cells. We determined the four subsets of γδ T cells, i.e. naïve (CD45RA (Table III) . We found no correlation between the capacity of γδ T cells to be expanded with Phosphostim and IL-2
and their naïve/memory phenotype.
Myeloma cell lines are efficiently killed by Phosphostim-expanded γδ T cells
γδ T cells expanded from HD display strong cytotoxic activity against some HMCLs in vitro (Kunzmann, et al 2000) . In order to determine the potential lytic capacity of expanded γδ T cells against a panel of HMCLs, we first used γδ T cells amplified from two HD by Phosphostim stimulation as described above (≥ 90% γδ purity). The Phosphostimexpanded γδ T cells efficiently killed the Burkitt's lymphoma Daudi cells, unlike Burkitt's lymphoma Raji cells known to be resistant to γδ T cells. Of interest, 13 out of 14 HMCLs were killed by these expanded γδ T cells. At an E:T ratio of 30:1, the percentage of lysed cells ranged from 10% to 60% (Fig 1A) . Only the XG-3 cells could not be killed by the various expanded γδ T cells. Pre-incubation of XG-3 cells with zoledronate did not abrogate their lysis resistance (data not shown).
In addition, expanded γδ T cells from 7 patients with MM killed 5 cell lines (Raji, RPMI 8226, XG-5, XG-6, and XG-19) as efficiently as those from 6 HD (results not shown). Fig 1B shows two representative experiments using XG-6 and XG-19 HMCLs as targets.
Expanded γδ T cells from patients with MM are able to kill primary MMC in vitro 51
As Cr could not be efficiently incorporated in primary MMC, the Cytoxilux assay kit was used to determine the cytotoxicity of γδ T cells toward purified primary MMC at different E:T ratios. Purified primary MMC were obtained from the PB of one patient with plasma cell leukemia (CD138 + : 86%) and from the bone marrow of a second patient using FACS sorting (CD138 + > 90%). The XG-6 HMCL was used as a control target. γδ T cells were expanded from the PB of one MM patient by Phosphostim. The lysis of primary MMC by γδ T cells was > 40% at a 30:1 E:T ratio (Fig 1C) .
Survival of expanded γδ T cells in medium without IL-2 and their effect on CD34 cells
We speculated that Phosphostim and IL-2-expanded γδ T cells would be starved of IL-2, at least transiently, after injection in vivo. To evaluate whether such starvation could affect their cytotoxic potential, γδ T cells were cultured with or without IL-2 for 48 hours and their survival and capacity to kill XG-6 cells were determined at 24h (results not shown) and at 48h. As shown in Fig. 2A , the lytic capacities of γδ T cells cultured for 48h with or without IL-2 were not significantly different (P = .465). Thus, deprivation of IL-2 did not significantly affect the survival and killing efficiency of expanded γδ T cells.
We next looked for the effect of expanded γδ T cells on the survival of CD34 cells that were purified from leucaphaeresis products. CD34 cells were pre-incubated with expanded γδ T cells at 30:1 and 5:1 ratios for 4 hours, and then seeded in methylcellulose semi-solid medium to evaluate their haematopoietic colony forming potential. The killing capacity of γδ T cells in this experiment was checked in the meantime using the XG-6 HMCL as described above (data not shown). As shown in Fig 2B, the ability of CD34 cells to form GM-CFU was unaffected by a pre-incubation with expanded γδ T cells (P =.873).
All the expanded γδ T cell lines expressed the chemokine (C-X-C motif) receptor 4 (CXCR4). Fig.2C depicts the expression of CXCR4 by four representative γδ T cell lines.
Discussion
Our results show that peripheral blood γδ T cells from patients with MM can be efficiently expanded in a short-time culture using Phosphostim and IL-2. These cells are highly cytotoxic against all but one HMCL and efficiently kill primary MMC.
The frequency of circulating γδ T cells has been reported to be reduced in cancer diseases (Katsuta, et al 2006 , Re, et al 2005 . We show here that the γδ T cell counts in the peripheral blood of patients with newly-diagnosed MM were similar to those of age-related HD. In addition, γδ T cell counts were not significantly affected in patients with MM relapsing from chemotherapy.
Although several authors showed a lower successful amplification (about 50%) of γδ T cell expansion in MM patients using pamidronate (Kunzmann, et al 2000 , Wilhelm, et al 2003 or zoledronate (Mariani, et al 2005) , we could not confirm this observation. For more than 70% of the patients with MM or for HD, a 14-day expansion rate greater than 100-fold was obtained both with Phosphostim or zoledronate. This may be explained by the fact that in the previous studies, the rate of successful amplification was evaluated on day 7 of culture with different criteria.
The function of γδ T cells from MM patients was also comparable to those from HD.
Phosphostim-amplified γδ T cells efficiently killed 13/14 HMCLs and primary myeloma cells. In humans, it was reported that many molecules, such as LFA-1, CD2 (Kato, et al 2003, Wang and Malkovsky 2000) , and MICA-MICB/NKG2D (Bauer, et al 1999 , RinconOrozco, et al 2005 In addition to their killing of HMCLs, we show here that Phosphostim and IL-2 expanded γδ T cells could also efficiently kill patients' primary MMC, emphasizing the attraction of these cells for immunotherapy.
To foresee a clinical trial of adoptive therapy with γδ T cells, we have answered three requirements: 1) the feasibility of expanding enough γδ T cells. Starting from one leucaphaeresis harvested at diagnosis or at relapse after various chemotherapy treatments, a ≥100-fold γδ T cell expansion can be achieved in about 70% of patients with a 78% purity in γδ T cells, insuring the obtaining of 2 x 10 9 γδ T cells, which represent an adequate amount of cells to treat patients. However, our current data show that at least 2 x 10 9 γδ T cells will be hardly obtained after a CTX + G-CSF mobilization regimen because of T cell (including γδ T cell) depletion induced by CTX . In addition, in patients with a successful γδ T cell amplification rate (≥ 100 fold) at the time of HSC mobilization, the purity of γδ T cells was found to be about 11%. The remaining 89% cells γδ T cells (Kobayashi, et al 2007) . Few objective clinical responses were observed. However, in that study, γδ T cells were activated by a natural phosphoantigen which has been shown to be less effective than BrHPP/Phosphostim (Espinosa, et al 2001) . We found no predictive marker for a successful expansion, particularly according to the γδ T cell effector/memory phenotype.
Thus, we suggest using a pre-screening expansion assay before performing a large volume leucaphaeresis. 2) We looked for the ability of γδ T cells to keep their cytotoxic capacity upon deprival of IL-2. Noteworthy, no detectable IL-2 could be detected in the aplasia window 5-10 days post high dose melphalan (unpublished data). We found here that a 2-day IL-2 deprivation did not abrogate the cytotoxic potential of γδ T cells, suggesting that the injected γδ T cells will keep their cytotoxic ability in vivo. 3) We demonstrated that expanded γδ T cells had no cytotoxic activity toward haematopoietic stem cells, with regard to their ability to generate 14 day-haematopoietic colonies.
Thus, we would recommend injecting γδ T cells in the lymphoid and haematopoietic depletion window occurring 5-10 days after high dose melphalan and graft of haematopoietic stem cells. In this window, the leukocyte count in the bone marrow is minimum (10 5 cells/L) and comprises mainly MMC that have escaped melphalan. The expanded γδ T cells expressed CXCR4 (Fig. 2C) , the receptor for SDF-1, which controls homing of haematopoietic stem cells and myeloma cells into bone marrow (Alsayed, et al 2006 , Chute 2006 , Gazitt and Akay 2004 . Thus, we may expect that these γδT cells will home to the bone marrow, have easy access to the chemoresistant myeloma cells, and provide a second cytotoxic hit to fully kill them, without killing the haematopoietic stem cells that are necessary to repair haematopoietic tissue.
In addition, it was shown recently that γδ T cells were also professional antigen-presenting cells (Brandes, et al 2005) . A large panel of adhesion and costimulatory molecules like CD40, CD54, CD80, and CD86 were expressed in our expanded γδ T cells from 7 HD and 13 patients with MM (results not shown). Taking these above results together, adoptive immunotherapy using γδ T cells probably has two different roles, one to act as effector cells directly against tumour cells and the other to act as APC for a tumour vaccine.
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